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Bauer et al. have described an elevation in plasma fucosyltransferase activity in plasma of patients with neoplastic disease (1) . Three assays were performed: transfer of fucose onto endogenous plasma acceptors, transfer of fucose onto the 2'-position of the terminal galactose of desialated fetuin (a2-fucosyltransferase), and transfer of fucose onto the 3'-position of the terminal N-acetylglucosamine of desialodegalactofetuin (a,-fucosyltransferase). While the data cannot be disputed, it appears that the enzymatic activities they actually measured are different from those that they described.
An acceptor with terminal galactose and subterminal N-acetylglucosamine such as desialated fetuin can accept fu- Since plasma may contain endogenous acceptors for several fucosyltransferases, it seems unlikely that the activity of SCIENCE, VOL. 204, 11 MAY 1979 any individual enzyme can be deduced by subtraction of an "endogenous'' level of activity from results obtained by addition of an exogenous acceptor. Furthermore, we have shown (6) utilizing N-acetylglucosamine terminal acceptors that the plasma level of fucosyltransferase rises markedly during bone marrow hyperplasia after chemotherapy. A specific inhibitor of endogenous activity of other plasma fucosyltransferases was used in the latter study. In Kessel's comment (1) on our report (2) was surprising since he and his co-workers use, in principle, the same assay system as we (3) .
The hydrogen ion-dependent fucosyltransferase adds fucose primarily to the terminal galactose residues of both glycoproteins (4) and glycolipids (5) by forming (I --2) linkages. Only when using a low molecular weight acceptor such as N-acetyllactosamine are considerable amounts also transferred to N-acetylglucosamine (6) . Though N-ethylmaleimide (NEM) preferentially, not exclusively, inhibits a,-fucosyltransferase, a:-fucosyltransferase can be affected as well. It has been recently reported (7) that in a patient with leukemia, the activity of a3-fucosyltransferase was inhibited by 55 We determined the acceptor for a:rfucosyltransferase from the literature (5, 6). Our report (2) states that a3-fucosyltransferase adds L-fucose at the C-3 atom of N-acetylglucosamine. Since a terminal N-acetylglucosamine on the acceptor is essential for enzyme activity (9) , and since this prerequisite is fulfilled by desialodegalactofetuin, desialofetuin (as used as the acceptor for a2-fucosyltransferase) is a very poor acceptor for a:,-fucosyltransferase.
The observation of elevated plasma fucosyltransferase activity during bone marrow hyperplasia does not contradict our findings. We had previously demonstrated (10) that a substantial increase of serum glycosyltransferases (apart from deterioration of cell function) is due to proliferative and secretory processes of neoplastic or even normal cells. CHRISTIAN H. BAUER Biochemisches Institut der AlbertLudwigs-Universitat, Hermann-HerderStr. 7, D-7800 Freiburg, Germany
